Company / EPS (Diluted)
Arbutus Biopharma Corp EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.38
FY2025
5-year range
-$1.00 / -$0.38
FY2021-FY2025
Trend
+13.6%
vs FY2024
Sector context
#64 of 204
Health Care
What the data says
At $-0.38, Arbutus Biopharma Corp's eps (diluted) ranks #64 of 204 in the Health Care sector. EPS (Diluted) has increased for 5 consecutive years, from $-2.89 in FY2020 to $-0.38 in FY2025.
Based on SEC 10-K filings.
-0.38 in FY2025.
Improved from $-0.46 to $-0.38 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#64 of 204 in Health CareTop 31% of 204This company -$0.38 Sector average -$0.89
▼
+57.1% above sector average
Key checks
Key Insights
- Arbutus Biopharma Corp's eps (diluted) has grown for 5 consecutive years.
- In FY2025, eps (diluted) increased 13.6% year-over-year.
- Ranks #64 out of 204 companies in the Health Care sector.
- Lowest eps (diluted) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -11.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.38 | +13.6% |
| FY2024 | -$0.44 | +4.3% |
| FY2023 | -$0.46 | +44.6% |
| FY2022 | -$0.83 | +17.0% |
| FY2021 | -$1.00 | +65.4% |
| FY2020 | -$2.89 | -489.8% |
| FY2019 | -$0.49 | +68.6% |
| FY2018 | -$1.56 | +0.0% |
| FY2017 | -$1.56 | +78.5% |
| FY2016 | -$7.24 | -424.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026